<PAGE>

                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

                    QUARTERLY REPORT FOR THE QUARTERLY PERIOD
                              ENDED MARCH 31, 2006

                           COMMISSION FILE NO. 0-28077

                                 GENELINK, INC.
                 (Name of Small Business Issuer in its charter)

<TABLE>
<S>                                                          <C>
              PENNSYLVANIA                                        23-2795613
     (State or other jurisdiction of                           (I.R.S. Employer
      incorporation or organization                          Identification No.)
</TABLE>

<TABLE>
<S>                                                                 <C>
        Newport Financial Center
        113 Povonia Avenue, #313
             Jersey City, NJ                                        07310
(Address of principal executive offices)
</TABLE>

                    ISSUER'S TELEPHONE NUMBER: (800) 558-4363

     Check whether the Issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days.

Yes   X   No
    -----    -----

     Indicated by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).

Yes       No   X
    -----    -----

     APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares
outstanding of each of the issuer's classes of common stock, as of the latest
practicable date.

<TABLE>
<S>                                <C>
Number of Shares of Common Stock
   Outstanding on May 1, 2006      36,357,868
</TABLE>

     Transitional Small Business Disclosure Format

Yes       No   X
    -----    -----

<PAGE>

                          GENELINK, INC. AND SUBSIDIARY

<TABLE>
<CAPTION>
                                                                        Page No.
                                                                        --------
<S>                                                                     <C>
PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements.

        Consolidated Balance Sheets at March 31, 2006 (unaudited) and
        December 31, 2005                                                    3

        Consolidated Statements of Operations for the three months
        ended March 31, 2006 and 2005 (unaudited)                            4

        Consolidated Statements of Cash Flows for the three months
        ended March 31, 2006 and 2005 (unaudited)                          5-6

        Notes to Interim Consolidated Financial Statements                 7-8
</TABLE>


                                       -2-

<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                                                     CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                     (UNAUDITED)
                                                                   MARCH 31, 2006   DECEMBER 31, 2005
                                                                   --------------   -----------------
<S>                                                                <C>              <C>
ASSETS
   Cash and cash equivalents                                        $     12,719      $     15,275
   Accounts receivable                                                    50,578            32,651
   Inventory                                                               2,077             3,261
   Prepaid expenses                                                       29,855            37,435
                                                                    ------------      ------------
      Total current assets                                                95,229            88,622

Property and equipment                                                   150,202           147,519
Other assets                                                             215,861           209,135
                                                                    ------------      ------------
               Total assets                                         $    461,292      $    445,276
                                                                    ============      ============

LIABILITIES
   Accounts payable and accrued expenses                            $    449,935      $    429,165
   Accrued payroll taxes                                                   7,342             7,454
   Loans payable                                                         174,360            27,861
                                                                    ------------      ------------
      Total current liabilities                                          631,267           464,480
Accrued compensation                                                     622,630           593,399
                                                                    ------------      ------------
               Total liabilities                                       1,254,267         1,057,879
                                                                    ------------      ------------

SHAREHOLDERS' EQUITY (DEFICIENCY)
   Common stock, $.01 par value, 75,000,000 shares authorized,
      37,089,538 and 36,689,550 shares issued, 36,683,369
      and 36,283,381 outstanding as of March 31, 2006 and
      December 31, 2005, respectively                                    370,896           366,896
Additional paid in capital                                             6,955,280         6,910,160
Stock warrants                                                         2,961,809         2,961,809
Accumulated deficit                                                  (10,765,905)      (10,536,413)
Treasury stock, 406,169 shares as of March 31, 2006 and
   December 31, 2005, at cost                                           (315,055)         (315,055)
                                                                    ------------      ------------
         Total shareholders' equity (deficiency)                        (792,975)         (612,603)
                                                                    ------------      ------------
         Total liabilities and shareholders' equity (deficiency)    $    461,292      $    445,276
                                                                    ------------      ------------
</TABLE>

               THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THE
                        CONSOLIDATED FINANCIAL STATEMENTS


                                       -3-

<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                                           CONSOLIDATED STATEMENTS OF OPERATIONS
                                                                     (UNAUDITED)

<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,                        2006          2005
----------------------------                    -----------   -----------
<S>                                             <C>           <C>
REVENUE                                         $    47,711   $   155,581
COSTS OF GOODS SOLD                                  16,749        29,907
                                                -----------   -----------
GROSS PROFIT                                         30,962       125,674
                                                -----------   -----------

EXPENSES
   Selling, general and administrative              106,432       288,441
   Consulting                                        49,320        60,523
   Professional fees                                 86,600        70,069
   Advertising and promotion                          5,249        71,455
   Amortization and depreciation                     12,852         6,674
                                                -----------   -----------
                                                    260,453       497,162
                                                -----------   -----------

NET LOSS BEFORE PROVISION FOR INCOME TAXES         (229,491)     (371,488)
PROVISION FOR INCOME TAXES                                0             0
                                                -----------   -----------
NET LOSS                                        $  (229,491)  $  (371,488)
                                                -----------   -----------
NET LOSS PER SHARE, BASIC & DILUTED             $     (0.01)  $     (0.01)
                                                -----------   -----------
   Weighted average common shares and diluted
      potential common shares                    36,777,316    33,456,525
                                                ===========   ===========
</TABLE>

               THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THE
                       CONSOLIDATED FINANCIAL STATEMENTS.


                                       -4-
<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                                           CONSOLIDATED STATEMENTS OF CASH FLOWS
                                                                     (UNAUDITED)

<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,                                     2006        2005
----------------------------                                  ---------   ---------
<S>                                                           <C>         <C>
CASH FLOWS FROM OPERATING ACTIVITIES
   Net loss                                                   $(229,491)  $(371,488)
   Adjustments to reconcile net loss to net cash used in
      operating activities
      Depreciation and amortization                              12,852       6,674
      Amortization of discounts on loans payable                  5,480      22,791
      Fair value of options granted for consulting services          --      11,520
      Changes in operating assets and liabilities
         Accounts receivable                                    (17,927)    (32,497)
         Inventory                                                1,184       3,662
         Prepaid expenses                                         7,580       9,112
         Other assets                                                --     (11,254)
         Accounts payable and accrued expenses                   20,770     155,267
         Accrued payroll taxes                                     (112)     (7,664)
         Accrued compensation                                    29,231      26,574
                                                              ---------   ---------
Net cash used in operating activities                          (170,433)   (187,303)
                                                              ---------   ---------

CASH FLOWS FROM INVESTING ACTIVITIES
   Capital expenditures                                         (11,237)         --
   Patent acquisition costs                                     (11,025)     (9,946)
                                                              ---------   ---------
Net cash used in investing activities                           (22,262)     (9,946)
                                                              ---------   ---------

CASH FLOWS FROM FINANCING ACTIVITIES
   Proceeds from loans and note payable                         183,440          --
   Repayment of loan payable                                    (17,861)    (25,000)
   Proceeds relating to issuance of common stock, net            24,560     117,500
                                                              ---------   ---------
Net cash provided by financing activities                     $ 190,139   $  92,500
                                                              ---------   ---------
</TABLE>

    THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THE CONSOLIDATED FINANCIAL
                                   STATEMENTS.


                                       -5-

<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                                           CONSOLIDATED STATEMENTS OF CASH FLOWS
                                                                     (UNAUDITED)

<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,                       2006       2005
----------------------------                     -------   ---------
<S>                                              <C>       <C>
NET DECREASE IN CASH AND
   CASH EQUIVALENTS                              $(2,556)  $(104,749)
Cash and cash equivalents, beginning of period    15,275     155,689
                                                 -------   ---------
Cash and cash equivalents, end of period         $12,719   $  50,940
                                                 -------   ---------

SUPPLEMENTARY CASH FLOW INFORMATION
   Cash paid for interest                        $   265          --

NON-CASH FINANCING TRANSACTIONS:
   Issuance of common stock for services              --   $  51,150
   Stock warrants granted for services                --   $  39,420
</TABLE>

    THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THE CONSOLIDATED FINANCIAL
                                   STATEMENTS.


                                       -6-

<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                              NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1 - DESCRIPTION OF ORGANIZATION

                                  ORGANIZATION

                                  GeneLink, Inc. (the Company) and Subsidiary
                                  (Dermagenetics, Inc.) operate in New Jersey.
                                  The Company was organized under the laws of
                                  the Commonwealth of Pennsylvania and
                                  Dermagenetics, Inc. was organized under the
                                  laws of the State of Delaware. The Company is
                                  the successor to a Delaware corporation
                                  organized under the same name on September 21,
                                  1994. The Company's offices are located in
                                  Jersey City, New Jersey.

                                  The Company was founded in response to the
                                  information being generated in the field of
                                  human molecular genetics. Scientists are
                                  discovering an increasing number of
                                  connections between genes and specific
                                  diseases or physical attributes and
                                  tendencies. These findings are a direct result
                                  of the National Institute of Health Genome
                                  Project.

                                  The Company has developed and received a
                                  patent on a DNA Collection Kit (R) for the
                                  collection of DNA specimens of clients. The
                                  kit is classified as a non-medical device.

                                  The Company has also developed proprietary
                                  SNP-based genetic profiles (named GeneLink
                                  Nutragenetic Profile (TM) and Dermagenetics
                                  (R) profiles. These profiles provide a means
                                  of predicting an individual's inherent genetic
                                  capacity to combat such conditions as
                                  oxidative stress and other important selected
                                  areas of physiologic health. The profiles, for
                                  example, can measure a person's potential to
                                  efficiently control oxygen free radical
                                  damage, eliminate hydrogen peroxide, protect
                                  and repair oxidized phospholipids and destroy
                                  harmful environmental compounds. The Company's
                                  profile assessment enables nutritional and
                                  skin care companies and health care
                                  professionals to recommend a specific and
                                  targeted regime of antioxidant vitamins,
                                  nutrients or skin care formulations that have
                                  been specifically designed to compensate for
                                  predicted deficiencies and to help provide
                                  individuals the best of health and appearance.


                                       -7-

<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                              NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

2 - BASIS OF PRESENTATION         The accompanying unaudited consolidated
                                  financial statements have been prepared by the
                                  Company in accordance with the instructions to
                                  Form 10-QSB and Article 10 of Regulation S-X
                                  relating to interim financial statements.
                                  Accordingly, they do not include all of the
                                  information and footnotes required by
                                  generally accepted accounting principles for
                                  complete financial statements and should be
                                  read in conjunction with the consolidated
                                  financial statements and notes thereto
                                  included in the Annual Report on Form 10-KSB
                                  of GeneLink, Inc. and Subsidiary for the year
                                  ended December 31, 2005.

                                  In the opinion of management, all adjustments
                                  (consisting of normal recurring accruals)
                                  necessary to present fairly the information
                                  set forth in the accompanying consolidated
                                  financial statements have been included. The
                                  results reported in these consolidated
                                  financial statements for the three-month
                                  period ended March 31, 2006 should not be
                                  regarded as necessarily indicative of results
                                  that may be expected for the year ending
                                  December 31, 2006.

3 - LOANS PAYABLE                 In January 2006, the Company entered into a
                                  Bridge Loan Agreement pursuant to which the
                                  Company borrowed $200,000 and pledged all of
                                  its intellectual assets as collateral. The
                                  Bridge Loan Financing accrues interest at a
                                  rate of 12% per year and matures on December
                                  31, 2006. In connection with the Bridge Loan
                                  Agreement, the Company issued 400,000 shares
                                  of common stock to the Bridge Lenders.


                                       -8-

<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

     Statements in this Report that relate to future results and events are
based on the Company's current expectations. Actual results in future periods
may differ materially from those currently expected or desired because of a
number of risks and uncertainties. For a discussion of factors affecting the
Company's business and prospects, see "Item 2 - Management's Discussion and
Analysis of Financial Condition and Results of Operations - Factors Affecting
the Company's Business and Prospects."

     Operating results for the three-month period ended March 31, 2006 are not
necessarily indicative of the results that may be expected for the full fiscal
year.

LIQUIDITY AND CAPITAL RESOURCES

     For the three-month period ended March 31, 2006, the Company's primary
liquidity requirements have been the implementation and funding of its sales and
marketing efforts in the nutragenetics and dermagenetics fields, the payment of
compensation to officers and other employees and the payment of accounts
payable. In the first three months of 2006, the Company raised $208,000, through
the borrowing of $200,000 principal of bridge loan notes and though the issuance
of common stock and warrants.

     Cash and cash equivalents at March 31, 2006 amounted to $12,719 as compared
to $15,275 at December 31, 2005, a decrease of $2,556. During the first three
months of 2006, the Company's operating activities utilized $170,433, as
compared to $187,303 for the first three months of 2005, a decrease of $16,870.
Cash utilized during these periods partially funded the Company's net losses for
such periods.

     Investing activities utilized $22,262 for the three months ended March 31,
2006 as compared to utilizing $9,946 for the three months ended March 31, 2005,
an increase of $12,316. Financing activities provided $190,139 for the three
month period ended March 31, 2006 as compared to $92,500 for the three months
ended March 31, 2005, an increase of $97,639. Financing activities in the three
months ended March 31, 2006 resulted from the borrowing of $200,000 principal of
bridge loan notes and from the issuance of common stock and warrants.

     The Company will require approximately $1,000,000 to implement its sales
and marketing strategy for the balance of 2006 and to fund its working capital
requirements for the balance of 2006. The Company has authorized the sale of up
to $1,000,000 of convertible secured notes, which would include the conversion
of the $200,000 principal amount of, and all accrued interest on, the Company's
bridge loan financing entered into on January 12, 2006, upon which time the
bridge loan financing would no longer be outstanding. If the Company is not able
to secure such additional required funding, it will continue to realize negative
cash flow and losses and may not be able to continue operations.


                                       -9-

<PAGE>

COMPARISON OF THREE MONTHS ENDED MARCH 31, 2006 TO THREE MONTHS ENDED MARCH 31,
2005

FINANCIAL CONDITION

     Assets of the Company increased from $445,276 at December 31, 2005 to
$461,292 at March 31, 2006, an increase of $16,016. This increase was primarily
due to an increase in accounts receivable of 17,927.

     Liabilities of the Company increased from $1,057,879 at December 31, 2005
to $1,254,267 at March 31, 2006, an increase of $196,388. This increase in
liabilities was primarily caused by an increase in loans payable from $27,861 at
December 31, 2005 to $174,360 at March 31, 2006, as the Company entered into a
$200,000 bridge loan financing on January 11, 2006, an increase in accounts
payable and accrued expenses from $429,165 at December 31, 2005 to $449,935 at
March 31, 2006, an increase of $20,770, and an increase in accrued compensation
from $593,399 at December 31, 2005 to $622,630 at March 31, 2006, of which
$568,462 is owed to Robert P. Ricciardi, an officer and director of the Company
who has not received any payments for services rendered to the Company since
1998.

CURRENT YEAR PERFORMANCE AND EARNINGS OUTLOOK

     Revenues. Total revenues for the three months ended March 31, 2006 were
$47,711 as compared to $155,581 for the three months ended March 31, 2005, a
decrease of $107,870, primarily resulting from the Company's inability to
adequately fund its business plan and marketing and promotion efforts during the
past year. The Convertible Loan financing described above should enable the
Company to increase the funding of its marketing and promotion efforts.

     Expenses. Total expenses for the three months ended March 31, 2006 were
$277,202 as compared to $527,069 for the three months ended March 31, 2005, a
decrease of $249,867, primarily resulting from a decrease in selling, general
and administrative expenses from $288,441 for the three months ended March 31,
2005 to $106,432 for the three months ended March 31, 2006, a decrease of
$182,009, as the Company was required to reduce its overhead, along with a
decrease in advertising and promotion expense from $71,455 for the three months
ended March 31, 2005 to $5,249 for the three months ended March 31, 2006, a
decrease of $66,206. The Convertible Loan financing described above should
enable the Company to increase the funding of its marketing and promotion
efforts.

     Losses. The Company incurred a loss of $229,491 for the three months ended
March 31, 2006 as compared to a loss of $371,488 for the three months ended
March 31, 2005, a decrease of $141,997. This decrease in the amount of losses
incurred is due to the $249,867 decrease in expenses as partially offset by the
$107,870 decrease in revenues.

FACTORS AFFECTING THE COMPANY'S BUSINESS AND PROSPECTS

     There are a number of factors that affect the Company's business and the
result of its operations. These factors include the result of litigation
currently outstanding against the Company; general economic and business
conditions; the level of acceptance of the Company's products and services; the
rate and commercial applicability of advancements and discoveries in the
genetics field; and the Company's ability to enter into strategic alliances with
companies in the genetics, pharmaceutical and nutrition industries; the ability
of the Company to raise the


                                      -10-

<PAGE>

financing necessary to fund its business and marketing plan, fund its research
and development to pay salaries to its officers and employees and to pay its
accounts payable.

PART II. OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

     (a)  Exhibit No.

          31.1 Certificate of the Acting Chief Executive Officer and Acting
               Chief Financial Officer pursuant to Section 302 of the
               Sarbanes-Oxley Act of 2002.

          32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted
               pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     (b)  Reports on Form 8-K

          None

                                   * * * * * *

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                        GENELINK, INC.
                                        (Registrant)


Date: May 10, 2006                      By: /s/ Monte E. Taylor, Jr.
                                            ------------------------------------
                                            Monte E. Taylor, Jr.,
                                            Acting Chief Executive Officer and
                                            Acting Chief Financial Officer


                                      -11-